Patent

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vintage Wine, SolarEdge, Unisys, and Rent the Runway and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, December 3, 2022
United States District Court for the Eastern District of Texas, RTR, IPO, District court, Registration statement, SolarEdge, Defendant, Rent the Runway, UIS, Communication, United States International Trade Commission, Sale, Jewellery, NYSE, Unisys, PV, Form, VWE, Vintage Wine, EBITDA, Lilliput Kidswear, COVID-19, News, Growth, Prospectus, DC, Wine, Marketing, Register, Patent, Holding company, Renewable energy, Risk management, Audit, Pharmaceutical industry, Property management, AMPT, P.C

On September 13, 2022, Vintage Wine announced its financial results for fiscal year 2022.

Key Points: 
  • On September 13, 2022, Vintage Wine announced its financial results for fiscal year 2022.
  • Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects.
  • For more information on the Rent the Runway class action go to: https://bespc.com/cases/RENT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Is FTC v. Actavis Causing Pharma Companies to Change Their Behavior?

Retrieved on: 
Saturday, December 3, 2022
Supreme Court of the United Kingdom, Time, Improvement, United States Court of Appeals for the Third Circuit, Supreme, Supreme court, DOJ, Medicare Prescription Drug, Improvement, and Modernization Act, MMA, Review, Competition, FTC, Incidence, Goal, Commission, AG, Annual report, Law of the United Kingdom, Use, Empirical research, Third Circuit Court of the Supreme People's Court, Drug Price Competition and Patent Term Restoration Act, Congress, SGR Repeal and Medicare Provider Payment Modernization Act of 2014, Patent, Medicare, Bureau, Generic drug, Pharmaceutical industry, Actavis
Key Points: 

Baudax Bio Announces Pricing of $5 Million Public Offering

Retrieved on: 
Friday, December 2, 2022
NMB, Prospectus, Sale, NSAID, Form, COVID-19, National Railway Company of Belgium, Intellectual property, Park Avenue, SEC filing, Exercise, Therapy, 3rd Floor, Series, Pain, Security (finance), Patent

The closing of the offering is expected to occur on or aboutDecember 6, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or aboutDecember 6, 2022, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to beapproximately $5 million.
  • The Company intends to use the net proceeds from this offering for working capital, pipeline development activities and general corporate purposes.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

DENSO Receives IEEE Corporate Innovation Award for Developing and Spreading Use of QR Code

Retrieved on: 
Friday, December 2, 2022
QR code, Denso, Plant, Electronics, Electricity, Engineering, DENSO, Patent, Organization, IEEE, Consumer electronics, Television

KARIYA, Japan, Dec. 2, 2022 /PRNewswire/ -- DENSO Corporation today announced it has received the IEEE Corporate Innovation Award from IEEE,*1 the largest international association for electrical and electronic engineering in the world, for developing the QR Code*2 and spreading its use globally.

Key Points: 
  • KARIYA, Japan, Dec. 2, 2022 /PRNewswire/ --DENSO Corporation today announced it has received the IEEE Corporate Innovation Award from IEEE,*1 the largest international association for electrical and electronic engineering in the world, for developing the QR Code*2 and spreading its use globally.
  • Established by IEEE in 1985, the award has been presented to leading companies and organizations worldwide.
  • The QR Code was developed in 1994 by DENSO's applied equipment engineering section (currently DENSO WAVE) as an easy-to-read code that can store a large amount of information.
  • *2, 4, and5 QR Code, SQRC, and Frame QR are registered trademarks of DENSO WAVE Incorporated.

Global Drone Market Analysis and Technology Report 2022-2027: UAVs have Been Witnessing Wide Adoption Across Military Applications

Retrieved on: 
Friday, December 2, 2022
Drone, Aircraft, Publication, Lockheed Martin, Hammerhead usv-t, Northrop Grumman, Government, Northrop, Grumman, Oceaneering International, Research, Privacy, Robotics, Unmanned underwater vehicle, Software, Life, Element, AeroVironment, Patent, SZ, General Atomics, Risk, Unmanned aerial vehicle, UGV Interoperability Profile

UAVs have been witnessing wide adoption across many military applications, including air strikes, surveillance, traffic monitoring, rescue and search operations, bomb threats, hostage situation control and fugitive tracking.

Key Points: 
  • UAVs have been witnessing wide adoption across many military applications, including air strikes, surveillance, traffic monitoring, rescue and search operations, bomb threats, hostage situation control and fugitive tracking.
  • UAVs do not pose any threat to human life, and thus government agencies are adopting this technology to counter critical situations.
  • The report concludes with detailed profiles of the major vendors in the global drone market.
  • The scope of the report, however, does not include players operating in the drone insurance and the drone racing markets.

RNA Sequencing Services Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Health, Genetics, Other Science, Research, Science, Biotechnology, Lynx, National Institutes of Health, Sequence, Porter's five forces analysis, Abraxis BioScience, MENA, Research, RNA, NIH, Maintenance, Gene, Benchmarking, Patent, CPC, Type, Services marketing, Organization, NGS, Fine chemical, Vaccine, Antibiotics, Phosphorus, Illumina, Nanopore

The 'RNA Sequencing Services Market'' report features an extensive study of the current market landscape and future potential of the RNA sequencing services market.

Key Points: 
  • The 'RNA Sequencing Services Market'' report features an extensive study of the current market landscape and future potential of the RNA sequencing services market.
  • Currently, more than 70 companies offer services related to RNA sequencing.
  • A general overview of RNA sequencing, along with information on the key steps involved in the process, details on the various types, methods and applications of RNA sequencing, as well as the advantages and limitations associated with RNA sequencing.
  • Which type of next generation sequencing kits are being used to collect samples for RNA sequencing?

Insights on the Sleep Aid Global Market to 2028 - by Energy Source, Mode of Water Supply, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Health, Other Health, Geography, Compartment syndrome, Sudden death, Sleep disorder, Triple, Quality of life, Sleep, United Nations, News, Hypertension, Stroke, Tobacco, Degenerative disease, Growth, Prevalence, Insomnia, National Sleep Foundation, Ageing, OTC, Pain, Patent, Sleep apnea, Walking, Agriculture, Pharmaceutical industry, Marketing

In reality, lack of sleep can contribute to a variety of issues, lowering the quality of life in adults over the age of 65.

Key Points: 
  • In reality, lack of sleep can contribute to a variety of issues, lowering the quality of life in adults over the age of 65.
  • Among these, sleep apnea is a sleep breathing disorder in which the upper airway collapses during sleep.
  • North America has been predicted to dominate the global sleep aid market.
  • Asia-Pacific is anticipated to exhibit significant growth in the global sleep aid market.

Esōes Cosmetics Smart Safety Beauty Products Now Available for Pre-Sale

Retrieved on: 
Friday, December 2, 2022
Sale, Rape, Woman, Statistics, Safety, Entrepreneurship, Cosmetics, Benzodiazepine, Flunitrazepam, Domestic violence, Ecosystem, Violence, Patent, LAS, Bluetooth

LAS VEGAS, Dec. 2, 2022 /PRNewswire/ -- Esōes Cosmetics is launching the first patent-pending Liquid Lipstick with smart safety features all within the Bluetooth connected product. With the first lipsticks set to ship in early 2023, five different shades of Esōes Cosmetics' Liquid Lipstick are now available for presale at esoescosmetics.com.

Key Points: 
  • With the first lipsticks set to ship in early 2023, five different shades of Eses Cosmetics' Liquid Lipstick are now available for presale at esoescosmetics.com .
  • Eses Cosmetics Liquid Lipsticks are now available for pre-sale.
  • Eses Cosmetics is an ecosystem of solutions anchored in patent pending products and community outreach.
  • Our three pillars are: innovative smart safety cosmetics, a responsive giving model, & education.

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

Retrieved on: 
Friday, December 2, 2022
IND, Neuro, COVID-19, Mental health, Neuropathic pain, Degenerative disease, Lysergic acid diethylamide, Disorder, Anxiety, Post-traumatic stress disorder, Research, Conference, Physical disorder, Depression, LSD, Patent, CSE, Pharmaceutical industry, Phoenix, Neuroscience

Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.

Key Points: 
  • Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.
  • Furthermore, the data shows that BETR-001 promotes structural neuroplasticity in brain neurons and this effect is partly mediated by the activation of 5-HT2A receptor.
  • BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and other respiratory viral infections.
  • The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

Retrieved on: 
Friday, December 2, 2022
Biotechnology, Medicine, Investigational New Drug, COVID-19, Cell engineering, Annual report, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, Gene editing, Patient, Disease, Security (finance), Patent, Food, Pharmaceutical industry, IND, Beam

BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

Key Points: 
  • BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.
  • We believe the future of cell therapy involves high levels of cell engineering, enabled by multiplex base editing technology.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.